ActivBiotics Assignee Issues First Distribution of Cash to Creditors
6/20/2008 11:05:19 AM
More...
|
ActivBiotics' Intellectual Property Assets, Including Drug Product Candidates, Sold for $3.5 Million
4/3/2008 7:45:05 AM
More...
|
ActivBiotics' Intellectual Property Assets, Including Drug Product Candidates, Sold for $3.5 Million
4/2/2008 2:34:31 PM
More...
|
ActivBiotics Receives FDA Orphan Drug Designation for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis of Cancer
3/6/2008 7:03:49 AM
More...
|
ActivBiotics Set to Sell Proprietary Assets, Including Drug Product Candidates, on March 14, 2008
3/5/2008 7:44:35 AM
More...
|
ActivBiotics Proposes Development Strategy for Its Novel Rifamycin Antibiotics
2/25/2008 8:13:36 AM
More...
|
ActivBiotics Outlines a Clinical Path Forward to Examine if Rifalazil Is Superior to Azithromycin in the Treatment of Chlamydia STD
2/19/2008 6:58:33 AM
More...
|
ActivBiotics Receives Orphan Drug Designation from the European Medicines Agency for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis Indication
2/5/2008 7:30:12 AM
More...
|
ActivBiotics Completes Sale of Fixed Assets
1/29/2008 7:07:39 AM
More...
|
ActivBiotics Completes Sale of Fixed Assets; Expands Due Diligence Candidates
1/28/2008 2:58:47 PM
More...
|
|